Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Sam Lai
AddedMar 31, 2024
UpdatedMay 31, 2026
Sam Lai

Sam Lai

Founder & CEO, Mucommune

CrunchbaseLinkedIn

Sam Lai's Career

Mucommune
Mucommune

Durham, NC, US

Founder & CEO· C-Suite · Management
Inhalon Biopharma
Inhalon Biopharma

Durham, NC, US

Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Sam Lai's Career

Mucommune
Mucommune
Angel$36.5k82015Durham, NC, US
Founder & CEO· C-Suite · Management

Similar to Mucommune

MuciMedMuciMedKalamazoo, MI, USDisease Treatmentest. 2005MuciMedKalamazoo, MI, US · est. 2005

Developing mucin proteins for GI disease treatment since 2005. Based in Kalamazoo, Michigan.

Angel · $200k6
InSitu BiologicsInSitu BiologicsWoodbury, MN, USDrug Deliveryest. 2014InSitu BiologicsWoodbury, MN, US · est. 2014

InSitu Biologics: An emerging biotech firm developing a prolonged-release drug delivery platform.

Series A · $7M13
Mechano-TherapeuticsMechano-TherapeuticsPhiladelphia, PA, USDrug Deliveryest. 2021Mechano-TherapeuticsPhiladelphia, PA, US · est. 2021

Philadelphia-based medical firm specializing in advanced drug delivery systems for enhanced therapy.

Pre-Seed · $800k9
Moat BiotechnologyMoat BiotechnologyOklahoma City, OK, USVaccinesest. 2022Moat BiotechnologyOklahoma City, OK, US · est. 2022

Oklahoma City software firm & biopharmaceutical company developing innovative vaccines.

Series A · $8M5
Inhalon Biopharma
Inhalon Biopharma
Seed$11.9M112018Durham, NC, US
Founder

Leadership at Inhalon Biopharma

John WhelanJohn WhelanCEO
Winnie H WanWinnie H WanBoard Member

Similar to Inhalon Biopharma

Alveolus BioAlveolus BioBirmingham, AL, USBiotherapeuticsest. 2020Alveolus BioBirmingham, AL, US · est. 2020

Alveolus Bio: Innovating FDA-approved therapeutics for lung diseases.

Series A · $7M7
Aer TherapeuticsAer TherapeuticsRaleigh, NC, USBiopharmaceuticalsest. 2014Aer TherapeuticsRaleigh, NC, US · est. 2014

Aer Therapeutics: Clinical-stage biopharma developing treatments for severe respiratory diseases.

Series A · $36M12
Transpire BioTranspire BioWeston, FL, USInhaled Medicinesest. 2022Transpire BioWeston, FL, US · est. 2022

Transire Bio: Innovating painless delivery of injectable drugs through inhaled medicine development.

Angel · $10k30
Halia TherapeuticsHalia TherapeuticsSalt Lake City, UT, USTherapeuticsest. 2017Halia TherapeuticsSalt Lake City, UT, US · est. 2017

Halia Therapeutics: Preclinical biopharma firm innovating therapies for inflammatory and neurological disorders.

Series C · $47.2M11

Sam Lai's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · Kakao

People Similar to Sam Lai

Alexandre DaSilvaAlexandre DaSilvaCo-Founder · MoxytechJason RoseJason RoseCo-Founder & CEO · Globin SolutionsMichael DwinellMichael DwinellCo-Founder · XLock BiosciencesSamuel J. MagazinerSamuel J. MagazinerCo-Founder · EnvirobeWei LuWei LuCo-Founder · CrossbarIman DaryaeiIman DaryaeiCo-Founder · TheraCea Pharma